2010年

November 17, 2010: Summary of Consolidated Financial Results (For the Second Quarter Ended September 30,2010)[Japanese Standard]
November 12, 2010: Approval Received for Orally Disintegrating Tablet of imidafenacin (INN), a Drug for Overactive Bladder
November 8, 2010: Extension of License Rights Regarding KRP-203
September 21, 2010: Regarding Today's Media Report
July 30, 2010: First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2011
June 8, 2010: RELEASE OF "MUCODYNE® DS50%"
May 26, 2010: Change of Business Name
May 26, 2010: New Medium-Term Business Plan Developed: "HOPE 100 Stage 1"
February 3, 2010: Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2010
January 18, 2010: MARKETING APPROVAL FOR "MUCODYNE® DS50%"
January 7, 2010: Application filed for Orally Disintegrating Tablet of imidafenacin (INN), a Drug for Overactive Bladder